BACKGROUND AND OBJECTIVES: Cardiac failure is directly affected by left ventricular (LV) dysfunction, and particularly LV systolic dysfunction is strongly associated with survival in ESRD patients. The aim of this study was to determine the prognostic value of reduced LV ejection fraction (LVEF) measured at the time of initiation of hemodialysis (HD) in incident HD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: 1254 consecutive ESRD patients who electively started HD therapy were screened by echocardiography within 1 month after its inception. They were divided into five groups according to LVEF levels with a decrease of 0.1 each and were followed up for up to 7 years. Survival was examined with the Kaplan-Meier method and compared using the log-rank test. RESULTS: Among the 1254 patients, LVEF levels ≥0.6, 0.5 to 0.6, 0.4 to 0.5, 0.3 to 0.4, and <0.3 were seen in 842 (67.1%), 247 (19.7%), 107 (8.5%), 41 (3.3%), and 17 (1.4%) patients, respectively. On Kaplan-Meier analysis, 7-year event-free rates from cardiovascular death were 84.2, 83.7, 73.6, 59.4, and 30.9% in order of groups with decreasing LVEF of 0.1 each, respectively. Seven-year event-free rates from all-cause death were 69.2, 61.7, 57.1, 45.9, and 23.1% in the respective groups. Even after adjustment for other risk factors, decreasing LVEF was a strong independent predictor for cardiovascular death. CONCLUSIONS: Reduced LVEF on starting HD therapy could stratify risk of cardiovascular and all-cause mortality in ESRD patients. Screening by echocardiography at start of HD therapy might be recommended to predict prognosis in patients with ESRD.
BACKGROUND AND OBJECTIVES:Cardiac failure is directly affected by left ventricular (LV) dysfunction, and particularly LV systolic dysfunction is strongly associated with survival in ESRDpatients. The aim of this study was to determine the prognostic value of reduced LV ejection fraction (LVEF) measured at the time of initiation of hemodialysis (HD) in incident HDpatients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: 1254 consecutive ESRDpatients who electively started HD therapy were screened by echocardiography within 1 month after its inception. They were divided into five groups according to LVEF levels with a decrease of 0.1 each and were followed up for up to 7 years. Survival was examined with the Kaplan-Meier method and compared using the log-rank test. RESULTS: Among the 1254 patients, LVEF levels ≥0.6, 0.5 to 0.6, 0.4 to 0.5, 0.3 to 0.4, and <0.3 were seen in 842 (67.1%), 247 (19.7%), 107 (8.5%), 41 (3.3%), and 17 (1.4%) patients, respectively. On Kaplan-Meier analysis, 7-year event-free rates from cardiovascular death were 84.2, 83.7, 73.6, 59.4, and 30.9% in order of groups with decreasing LVEF of 0.1 each, respectively. Seven-year event-free rates from all-cause death were 69.2, 61.7, 57.1, 45.9, and 23.1% in the respective groups. Even after adjustment for other risk factors, decreasing LVEF was a strong independent predictor for cardiovascular death. CONCLUSIONS: Reduced LVEF on starting HD therapy could stratify risk of cardiovascular and all-cause mortality in ESRDpatients. Screening by echocardiography at start of HD therapy might be recommended to predict prognosis in patients with ESRD.
Authors: S A Hunt; D W Baker; M H Chin; M P Cinquegrani; A M Feldman; G S Francis; T G Ganiats; S Goldstein; G Gregoratos; M L Jessup; R J Noble; M Packer; M A Silver; L W Stevenson; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; A K Jacobs; L F Hiratzka; R O Russell; S C Smith Journal: J Am Coll Cardiol Date: 2001-12 Impact factor: 24.094
Authors: John S Gottdiener; Robyn L McClelland; Robert Marshall; Lynn Shemanski; Curt D Furberg; Dalane W Kitzman; Mary Cushman; Joseph Polak; Julius M Gardin; Bernard J Gersh; Gerard P Aurigemma; Teri A Manolio Journal: Ann Intern Med Date: 2002-10-15 Impact factor: 25.391
Authors: Leila R Zelnick; Ronit Katz; Bessie A Young; Adolfo Correa; Bryan R Kestenbaum; Ian H de Boer; Nisha Bansal Journal: Am J Kidney Dis Date: 2017-01-28 Impact factor: 8.860
Authors: Martin Wagner; David Ansell; David M Kent; John L Griffith; David Naimark; Christoph Wanner; Navdeep Tangri Journal: Am J Kidney Dis Date: 2011-04-12 Impact factor: 8.860
Authors: Nisha Bansal; Martin Keane; Patrice Delafontaine; Daniel Dries; Elyse Foster; Crystal A Gadegbeku; Alan S Go; L Lee Hamm; John W Kusek; Akinlolu O Ojo; Mahboob Rahman; Kaixiang Tao; Jackson T Wright; Dawei Xie; Chi-yuan Hsu Journal: Clin J Am Soc Nephrol Date: 2013-02-14 Impact factor: 8.237
Authors: Diana Y Y Chiu; Nik Abidin; John Hughes; Smeeta Sinha; Philip A Kalra; Darren Green Journal: Int J Cardiovasc Imaging Date: 2016-07-27 Impact factor: 2.357